Wall St futures steady after weekly gains; Fed rate decision looms
ResMed (NASDAQ:RMD), a $39.7 billion medical device company with a GREAT financial health score according to InvestingPro, saw Chief Financial Officer Brett Sandercock sell 3,000 shares of company stock on September 2, 2025, at a price of $270.77, totaling $812,310. The stock currently trades at a P/E ratio of 28.1x and has maintained dividend payments for 14 consecutive years. Sandercock also exercised options to acquire 2,000 shares at $101.64, totaling $203,280.
Following the sale, Sandercock directly owns 87,745 shares of ResMed. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2025. The company maintains strong financials with a current ratio of 3.44 and operates with a moderate level of debt.
In other recent news, ResMed Inc . announced its fourth-quarter earnings for the fiscal year 2025. The company reported an earnings per share (EPS) of $2.55, surpassing analyst expectations of $2.48. However, its revenue came in at $1.3 billion, which was slightly below the anticipated $1.33 billion. Despite a 23% increase in non-GAAP diluted EPS and a 10% rise in group revenue, the company’s stock experienced a decline in aftermarket trading. These developments reflect the mixed financial results for the quarter. Investors will likely pay attention to how ResMed addresses the revenue shortfall in future quarters. Analyst firms have not provided further upgrades or downgrades based on these earnings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.